evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,199 questions · 1,226 findings · 451 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 289 · 23.6%GRADE not reported 121 · 9.9%Very low 350 · 28.5%Low 279 · 22.8%Moderate 139 · 11.3%High 48 · 3.9%

Higher BP target (< 150‐160/95‐105 mmHg) vs lower BP target (< 140/90 mmHg)

Serious adverse events: cardiovascular events · older adults with primary hypertension

Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).

1 finding from 1 review

Casirivimab/imdevimab vs placebo

Serious adverse events within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

It is very uncertain whether casirivimab/imdevimab changes serious adverse events within 6 months compared with placebo (very low certainty).

1 finding from 1 review

Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval

Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males

It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).

1 finding from 1 review

Two doses of HPV vaccine vs three doses of HPV vaccine

Serious adverse events at up to 5‐year · 9‐ to 15‐year‐old females

It is very uncertain whether two doses of HPV vaccine changes serious adverse events at up to 5‐year compared with three doses of HPV vaccine (very low certainty).

1 finding from 1 review

Intervention not reported

Adverse events Clinical manifestations · people with acute herpes zoster1

The intervention showed no clear difference in adverse events Clinical manifestations (high certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week)

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

It is very uncertain whether an extended NVP plus ZDV regimen administered to infants for 14 weeks changes infants with any Severe Adverse Events compared with sdNVP plus ZDV (1 week) (very low certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

Doxycycline vs prednisolone

Number of participants with grade 3‐4 (severe or life‐threatening) treatment‐related adverse events at 1 year (raw data) · bullous pemphigoid

Doxycycline probably leads to lower number of participants with grade 3‐4 (severe or life‐threatening)… compared with prednisolone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy

Adverse events ‐ Serious adverse events · people with inhibitors

Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy

Adverse events ‐ Serious adverse events · people without inhibitors

Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Calcineurin inhibitors ± steroids vs placebo/no treatment/supportive treatment/steroids

Adverse events ‐ infection at 36 months · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ infection at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).

1 finding from 1 review

Rotarix vs placebo

Serious adverse events: intussusception · children

Rotarix showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).

3 findings from 1 review